OPEN PEER REVIEW

Open Peer Review (OPR)

As a new feature for progressing towards transparency, we decided to open a new window for all of our editors as well as authors titled "**Open Peer Review**". We hope by this new facility, our reviewers will be more motivated and authors will be more satisfied with the review process. We believe that publishing our peer review reports could make a transparent and clear environment for all our efforts within a journal, but not all reviewers tend to publish their comments.

What is "Open Peer Review" process?

An "Open Peer Review" process is making the details of all review process (including reviewers, associate editors, and EICs comments) as "Public" as it is agreed by EIC, Authors, and reviewers.

Advantages of "Open Peer Review" process

- More transparency, constructiveness and tactful comments of the peer review process: leads to an increase in the quality of reviews
- More motivations for all involved roles in the review process
- Authors' satisfactions from the review process: Increases honesty between authors and reviewers
- Education of both authors and new students
- Prevents reviewers from following their individual agendas and leading to the detection of reviewers' conflicts of interests

You can find out more at:
https://sites.kowsarpub.com/kowsar/knowledgebase/category/tree.html#opr.html

Archives of Clinical Infectious Diseases
Article DOI: 10.5812/archcid.99952
Published in: Archives of Clinical Infectious Diseases: 15(3); e99952

Peer Review Report for "Efficacy and Tolerability of Daclatasvir/Sofosbuvir (Datex) in Patients with HIV-HCV Co-infection"

Author(s): Narjes Shokatpour, Shahnaz Sali, Batool Daneshpazhouh, Masoud Mardani

Review Timeline:

Submit Date: 14 Dec 2019
Revised Date: 9 Jul 2020
Accepted Date: 11 Jul 2020

Revision (0)

Here, you can see the **Reviewers**, **Associate Editors** and **EICs'** comments from the beginning to the end of the revision process.

REFEREE: Reviewer | **Revision** (0) 15 Jun 2020

Dear AE,
The manuscript is educational and has novel local information, some details need revision:
1- Please add the median of CD4 and HIV viral load before Datex treatment
2- Please write about indication of adding ribavirin
3- Please add about median time of ART therapy of patients before study
4- Please note about CD4 of 7 patients with drug adverse effect in comparison to other patients.
Thanks.

REFEREE: Reviewer | **Revision** (0) 23 Jun 2020

Dear AE,
I gladly review “Efficacy and tolerability of daclatasvir/sofosbuvir (Datex) in patients with HIV-HCV co-infection” My opinion is below:
- Given the prevalence of hepatitis C and HIV in the community and the importance of these diseases in terms of epidemiology and related cancer, this article is considered valuable.
- Here are some tips to help improve the quality of your article:
In terms of English writing, the article needs to be edited.

- As much as possible, I have corrected and commented on some grammatical errors in the text, but this amount of correction is not enough. Therefore, it is necessary for the esteemed authors to re-edit the article in English.
- The file in which the comments are written is attached.
- Apart from these minor corrections, is no need for other modifications.

So, this article is accepted and needs minor revision.
I hope my comments, this will further improve.
Thanks.

REFEREE: Associate Editor | **Revision** (0) 5 Jul 2020

Dear EIC,
The manuscript is studied, and there are some comments which should be addressed by the author. According to the comments, the document needs minor revision.
Kind regards,

REFEREE: EIC | **Revision** (0) 5 Jul 2020

Dear Author,
The reviewers' comments are mentioned. Please correct the details as mentioned above carefully according to the reviewers' request.
Thanks.

OPEN PEER REVIEW

Revision (1)

Reply to Reviewers

Ideally, the reviewing process can significantly improve the submitted manuscripts by allowing the authors to take into account the advice of reviewers. Author(s) must reply to all reviewers' comments in a separate Word file, point by point. A "**Reply to Reviewers**" document is submitted along with revised manuscript during submission of revised files, summarizing the changes that the authors made in response to the reviewers' comments. The responses to reviewers' comments specifies how the authors addressed each comment the reviewers made.

You can read the authors' responses to the reviewers' comments in the next page.

Response to Reviewers' Comments

Journal: Archives of Clinical Infectious Diseases

Title of Paper: Efficacy and tolerability of daclatasvir/sofosbuvir (Datex) in patients with HIV-HCV co-infection

We greatly appreciate the reviewers' positive feedback and constructive comments. We added new excerpts and make changes in our revised manuscript, and highlighted them by blue color for reviewer A, and green color for reviewer B.

Reviewer 1:

- In terms of English writing, the article needs to be edited.

Response: The paper was edited by a native.

Reviewer 2:

1- Please add the median of CD4 and HIV viral load before Datex treatment

Response: The information related to the median of CD4 and HIV viral load before Datex treatment is available in table 1.

2 Please write about indication of adding ribavirin

Response: we added the excerpt below to the patients and methods section.

"Adding RBV to the patient's treatment regimen might occur if the patient had cirrhosis , advanced fibrosis or history of HCV treatment."

3- Please add about median time of ART therapy of patients before study.

Response: we added the excerpt below to the result section.

“The onset of HIV treatment varied, from a few years prior to the HCV treatment to simultaneously with the onset of HCV treatment .”

4- Please note about CD4 of 7 patients with drug adverse effect in comparison of other patients

Response: There was no difference between CD4 of 7 patients with drug adverse effects and those of other patients.

OPEN PEER REVIEW

Revision (1)

Here, you can see the **Reviewers**, **Associate Editors** and **EICs'** comments from the beginning to the end of the revision process.

Masoud Mardani: EIC | **Revision (1)** 11 Jul 2020

Dear Author,
The document is reviewed carefully by the reviewers. According to their comments and your revisions as requested, this manuscript is accepted.
Thanks.